Mereo BioPharma (MREO) Income from Continuing Operations (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Income from Continuing Operations of 6719000.0 for Q1 2026, up 47.86% year-over-year from 4544096.2 in Q1 2025, and up 62.18% quarter-over-quarter from 17765000.0 in Q4 2025.
Mereo BioPharma (MREO) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Income from Continuing Operations for 4 consecutive years, with 6719000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 47.86% year-over-year to 6719000.0; the TTM figure through Mar 2026 stood at 46124000.0 (up 20.55% YoY), while the FY2025 annual figure was 52292000.0, up 3.37% from the prior year.
- Income from Continuing Operations climbed to 6719000.0 in Q1 2026 per MREO's latest filing, from 17765000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1751000.0 in Q2 2023 and bottomed at 17909000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 10968769.23 across 4 years, with a median of 12076000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 599.89% — and 2025, when it soared 53.18%.
- Mereo BioPharma's Income from Continuing Operations stood at 9109000.0 in 2023, then sank by 96.61% to 17909000.0 in 2024, then grew by 0.8% to 17765000.0 in 2025, then jumped by 62.18% to 6719000.0 in 2026.
- Business Quant data shows MREO's Income from Continuing Operations at 6719000.0 in Q1 2026, 17765000.0 in Q4 2025, and 7024000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | -7.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.01 Mn |
| Mar 31, 2026 | -6.72 Mn |
| Dec 31, 2025 | -17.77 Mn |
| Sep 30, 2025 | -7.02 Mn |
| Jun 30, 2025 | -14.62 Mn |
| Mar 31, 2025 | -12.89 Mn |
| Dec 31, 2024 | -17.91 Mn |
| Sep 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | -12.26 Mn |
| Mar 31, 2024 | -8.95 Mn |
| Dec 31, 2023 | -9.11 Mn |
| Sep 30, 2023 | -6.53 Mn |
| Jun 30, 2023 | -1.75 Mn |
| Mar 31, 2023 | -12.08 Mn |